Cyteir Therapeutics Inc. (CYT)

AI Score

Unlock

3.02

-0.07 (-2.27%)

At close: Mar 15, 2024, 8:00 PM

Cyteir Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q3 2020	Q2 2020	Q1 2020
Period Ending	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	834K	934K	1.03M	726K	400K	200K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Gross Profit	-834K	-934K	-1.03M	-726K	-400K	-200K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Income	-38.25M	-44.84M	-47.46M	-48.17M	-49.98M	-49.97M	-49.05M	-42.26M	-35.78M	-29.07M	-22.27M	-20.94M	-15.56M	-10.52M	-6.01M
Interest Income	4.38M	2.75M	1.54M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pretax Income	-33.22M	-40.73M	-44.45M	-46.06M	-49.08M	-49.74M	-48.92M	-42.13M	-35.67M	-29M	-22.21M	-20.82M	-15.46M	-10.43M	-5.93M
Net Income	-30.88M	-37.68M	-41.29M	-43.82M	-48.23M	-49.61M	-48.89M	-42.13M	-35.67M	-29M	-22.21M	-20.82M	-15.46M	-10.43M	-5.93M
Selling & General & Admin	13.39M	14.38M	13.61M	13.55M	14.57M	14.63M	13.62M	11.3M	9.16M	6.44M	4.89M	4.18M	2.71M	1.88M	1.01M
Research & Development	24.86M	30.46M	33.85M	34.62M	35.41M	35.34M	35.43M	30.96M	26.62M	22.63M	17.38M	16.77M	12.85M	8.63M	5M
Other Expenses	1.26M	1.97M	2.08M	2.11M	896K	230K	137K	133K	106K	67K	64K	120K	100K	91K	81K
Operating Expenses	38.25M	44.84M	47.46M	48.17M	49.98M	49.97M	49.05M	42.26M	35.78M	29.07M	22.27M	20.94M	15.56M	10.52M	6.01M
Interest Expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	38.25M	44.84M	47.46M	48.17M	49.98M	49.97M	49.05M	42.26M	35.78M	29.07M	22.27M	20.94M	15.56M	10.52M	6.01M
Income Tax Expense	-2.33M	-3.04M	-3.15M	-2.24M	-989K	-275K	-169K	-140K	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Shares Outstanding (Basic)	36.03M	35.74M	35.59M	35.38M	35.33M	35.28M	35.24M	35.14M	35.06M	2.34M	34.47M	23.89M	23.89M	23.89M	23.89M
Shares Outstanding (Diluted)	36.03M	35.74M	35.59M	35.38M	35.33M	35.28M	35.24M	35.14M	35.06M	2.34M	34.47M	23.89M	23.89M	23.89M	23.89M
EPS (Basic)	-0.87	-1.06	-1.16	-1.24	-1.37	-1.41	-5.9	-5.71	-5.59	-5.47	-0.83	-0.87	-0.65	-0.44	-0.25
EPS (Diluted)	-0.87	-1.06	-1.16	-1.24	-1.37	-1.41	-5.9	-5.71	-5.59	-5.47	-0.83	-0.87	-0.65	-0.44	-0.25
EBITDA	-37.87M	-44.39M	-46.95M	-47.5M	-49.48M	-49.52M	-48.66M	-41.92M	-35.34M	-28.65M	-21.88M	-20.59M	-15.31M	-10.37M	-5.94M
EBIT	-8.83M	-8.83M	-8.83M	-8.83M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Depreciation & Amortization	995K	1.05M	1.12M	668K	638K	593K	535K	479K	434K	416K	387K	351K	256K	149K	67K